Klaudyna Fidyt

1.2k total citations · 2 hit papers
15 papers, 780 citations indexed

About

Klaudyna Fidyt is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Klaudyna Fidyt has authored 15 papers receiving a total of 780 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Hematology and 4 papers in Oncology. Recurrent topics in Klaudyna Fidyt's work include CAR-T cell therapy research (4 papers), Acute Lymphoblastic Leukemia research (4 papers) and Acute Myeloid Leukemia Research (3 papers). Klaudyna Fidyt is often cited by papers focused on CAR-T cell therapy research (4 papers), Acute Lymphoblastic Leukemia research (4 papers) and Acute Myeloid Leukemia Research (3 papers). Klaudyna Fidyt collaborates with scholars based in Poland, Netherlands and Norway. Klaudyna Fidyt's co-authors include Anna Fiedorowicz, Leon Strządała, Antoni Szumny, Małgorzata Firczuk, Joanna Stachura, Małgorzata Bobrowicz, Antoni Domagała, Agata Pastorczak, Martyna Poprzeczko and Agnieszka Graczyk‐Jarzynka and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Cancer Research.

In The Last Decade

Klaudyna Fidyt

14 papers receiving 770 citations

Hit Papers

β‐caryophyllene and β‐caryophyllene oxide—natural compoun... 2016 2026 2019 2022 2016 2025 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. β‐caryophyllene and β‐caryophyllene oxide—natural compounds of anticancer and analgesic properties
    2016 505 citations Klaudyna Fidyt, Anna Fiedorowicz et al. Cancer Medicine profile →
  2. CAR-T cell therapy for cancer: current challenges and future directions
    2025 40 citations Klaudyna Fidyt, Vladimir Mulens‐Arias et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Klaudyna Fidyt Poland 10 270 231 216 108 90 15 780
Souren Paul South Korea 18 434 1.6× 224 1.0× 196 0.9× 79 0.7× 49 0.5× 27 897
Zhunan Gong China 17 341 1.3× 132 0.6× 119 0.6× 75 0.7× 95 1.1× 40 933
Svitlana Shinkaruk France 16 345 1.3× 212 0.9× 325 1.5× 72 0.7× 94 1.0× 37 948
Chadarat Ampasavate Thailand 19 353 1.3× 96 0.4× 91 0.4× 91 0.8× 86 1.0× 44 905
Namki Cho South Korea 16 429 1.6× 146 0.6× 78 0.4× 97 0.9× 60 0.7× 68 865
Leon Strządała Poland 18 547 2.0× 244 1.1× 220 1.0× 133 1.2× 90 1.0× 66 1.2k
Gallant Kar-Lun Chan Hong Kong 22 551 2.0× 134 0.6× 92 0.4× 79 0.7× 81 0.9× 35 1.0k
Ke Zhang China 20 649 2.4× 189 0.8× 87 0.4× 96 0.9× 78 0.9× 81 1.1k
Norlaily Mohd Ali Malaysia 16 277 1.0× 264 1.1× 310 1.4× 47 0.4× 78 0.9× 23 896
Donavon Charles Hiss South Africa 14 298 1.1× 146 0.6× 111 0.5× 49 0.5× 63 0.7× 35 903

Countries citing papers authored by Klaudyna Fidyt

Since Specialization
Citations

This map shows the geographic impact of Klaudyna Fidyt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaudyna Fidyt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaudyna Fidyt more than expected).

Fields of papers citing papers by Klaudyna Fidyt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaudyna Fidyt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaudyna Fidyt. The network helps show where Klaudyna Fidyt may publish in the future.

Co-authorship network of co-authors of Klaudyna Fidyt

This figure shows the co-authorship network connecting the top 25 collaborators of Klaudyna Fidyt. A scholar is included among the top collaborators of Klaudyna Fidyt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaudyna Fidyt. Klaudyna Fidyt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Fidyt, Klaudyna, Vladimir Mulens‐Arias, Marina Díaz‐Beyá, et al.. (2025). CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduction and Targeted Therapy. 10(1). 210–210. 40 indexed citations breakdown →
2.
Madzio, Joanna, Agata Pastorczak, Martyna Poprzeczko, et al.. (2024). Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitors. HemaSphere. 8(3). e56–e56. 1 indexed citations
3.
Graczyk‐Jarzynka, Agnieszka, Klaudyna Fidyt, Hakan Köksal, et al.. (2023). Efficient chimeric antigen receptor targeting of a central epitope of CD22. Journal of Biological Chemistry. 299(7). 104883–104883. 3 indexed citations
4.
Fidyt, Klaudyna, Agata Pastorczak, Nicholas T. Crump, et al.. (2022). Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax. Oncogene. 41(11). 1600–1609. 14 indexed citations
5.
Poprzeczko, Martyna, Agata Pastorczak, Klaudyna Fidyt, et al.. (2022). Abstract 3324: Optimizing the therapeutic potential of tyrosine kinase inhibitors in chemo-immunotherapy of B-cell acute lymphoblastic leukemia involving rituximab. Cancer Research. 82(12_Supplement). 3324–3324.
6.
Firczuk, Małgorzata, Klaudyna Fidyt, Giulia Pagano, et al.. (2022). A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia. Frontiers in Immunology. 13. 781364–781364. 5 indexed citations
7.
Fidyt, Klaudyna, Agata Malinowska, Bianka Świderska, et al.. (2022). Optimized Method for Cell Surface Protein Identification on Primary B-Cell Precursor Acute Lymphoblastic Leukemia Cells. Blood. 140(Supplement 1). 11519–11520. 1 indexed citations
8.
Firczuk, Małgorzata, et al.. (2022). CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies. Cells. 11(11). 1804–1804. 10 indexed citations
9.
Pastorczak, Agata, et al.. (2021). Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia. Cancers. 13(7). 1536–1536. 37 indexed citations
10.
Wachowska, Małgorzata, Joanna Stachura, Klaudyna Fidyt, et al.. (2020). Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy. Cancer Immunology Immunotherapy. 69(6). 1101–1112. 21 indexed citations
11.
Fidyt, Klaudyna, et al.. (2020). Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage—Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities. International Journal of Molecular Sciences. 21(16). 5776–5776. 18 indexed citations
12.
Firczuk, Małgorzata, et al.. (2019). Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy. Cancer Letters. 471. 1–11. 35 indexed citations
13.
Domagała, Antoni, et al.. (2018). Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy. International Journal of Molecular Sciences. 19(8). 2256–2256. 72 indexed citations
14.
Fidyt, Klaudyna, Anna Fiedorowicz, Leon Strządała, & Antoni Szumny. (2016). β‐caryophyllene and β‐caryophyllene oxide—natural compounds of anticancer and analgesic properties. Cancer Medicine. 5(10). 3007–3017. 505 indexed citations breakdown →
15.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Souren Paul Breakdown of academic impact, for papers by Zhunan Gong Breakdown of academic impact, for papers by Svitlana Shinkaruk Breakdown of academic impact, for papers by Chadarat Ampasavate Breakdown of academic impact, for papers by Namki Cho Breakdown of academic impact, for papers by Leon Strządała Breakdown of academic impact, for papers by Gallant Kar-Lun Chan Breakdown of academic impact, for papers by Ke Zhang Breakdown of academic impact, for papers by Norlaily Mohd Ali Breakdown of academic impact, for papers by Donavon Charles Hiss
Rankless by CCL
2026